Pharmaceuticals, Biotechnology and Life Sciences
Oxford Biomedica has signed a new Licence and Clinical Supply Agreement (LSA) with Bristol-Myers Squibb’s company, Juno Therapeutics to use Oxford Biomedica’s LentiVector platform for its application in CAR-T and TCR-T programmes in oncology and other indications.
Merck said on Tuesday it got top-line efficacy results from two its pivotal Phase 3 trials (COUGH-1 and COUGH-2) testing…
Yokogawa has developed the SU10 Single CellomeTM Unit, a device that uses a nanopipette*1 to inject substances such as genes and drugs and aspirate intracellular materials at target locations in individual cells
– Results published in first paper from 18-month analysis of ongoing pivotal Phase 3 trial were generally consistent with overall…
BioNTech SE said Monday its development a potential vaccine to induce immunity and prevent COVID-19 infection in response to the growing global health threat posed by the disease has seen rapid progress. BioNTech’s product candidate, BNT162, is a potential first-in-class mRNA vaccine in the worldwide effort against COVID-19.
John Butler, the President and Chief Executive Officer sent a message about precautions to help mitigate the spread of COVID-19…
The COVID-19 crisis continues to evolve rapidly and in recent days several governments in the markets in which Unibail-Rodamco-Westfield (“URW”)…
The World Health Organisation has issued a guideline to keep safety in schools. We have outlined the most important keys…
American president Donald Trump has announced radical measures last week; closing entering the USA for European citizens, curbing flights in general, and has announced a national emergency. Only two weeks earlier he was skeptical about the outbreak of the coronavirus in the USA.
How do pharmaceutical companies prophet from COVID-19? Do they make the profit?